~~<i id='DEDAADD7E4'><strike id='DEDAADD7E4'><tt id='DEDAADD7E4'><pre id='DEDAADD7E4'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

explore

fashion

author：hotspot 2025-09-28 02:31:49 - browse：9184

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： What to watch for from Zogenix and Amicus clinical trials

focus

Wikipedia

entertainment

knowledge

hotspot

focus

JonathanErnst/APInUkraine,alittlebitofgoodnewscangoalongway,andthelifesavingworkbeingdoneasaresultof

WSS

Chemotherapy shortages won’t get better under Biden’s latest plan

Why sickle cell disease is getting the first CRISPR treatment

STAT Report: Patient voices and perspectives

Will the FTC rein in IQVIA's health data empire?

AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

In the gardens at Boston Children's Hospital, families find sanctuary

explore

fashion

focus

Activists slam private health insurers over coverage restrictions

Why sickle cell disease is getting the first CRISPR treatment

As demand for Covid shots wanes, Moderna seeks its next success

Teach medical students about patients with intellectual disabilities

Anesthesiologist group: stop taking Ozempic before surgery

Roche’s Alnylam deal shows drug firms interested in heart drugs

State Dept. review finds Biden bears some blame for Afghanistan failures

US economic growth accelerated in 2nd quarter, exceeding expectations and quieting recession fears

How one medical school became remarkably diverse

What causes rare myocarditis in young men after Covid vaccines?

Wikipedia

Supreme Court wrestles with OxyContin maker's bankruptcy deal

After sickle

STAT letters to the editor on burnt

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

Congenital heart disease patients face new threat of heart failure

STAT Event – Decoding Clinical Trials: Venture Capitalists Talk Early Biotech R&D

entertainment

knowledge

hotspot

focus